Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):342–349. doi: 10.1097/QAI.0000000000001929

Table 2.

Percent change from baseline in aBMD, 25-hydroxyvitamin D, parathyroid hormone,and bone turnover markers among participants with complete data (N=69) (Mean±SD)

6 Months 12 Months
Percent Change P Value P Adjusted for TBF Percent Change P Value P Adjusted for TBF
DXA parameters
Lumbar spine aBMD
Low VitD 0.5 ± 3.1 0.34 0.51 0.4 ± 4.4 0.26 0.36
Moderate VitD -0.3 ± 3.5 -0.8 ± 4.6
Total hip aBMD
Low VitD 0.4 ± 2.9 0.47 0.21 -0.5 ± 3.1 0.74 0.51
Moderate VitD -0.1 ± 2.8 -0.8 ± 3.2
Femoral neck aBMD
Low VitD -0.7 ± 3.9 0.79 0.90 -1.1 ± 3.5 0.96 0.78
Moderate VitD -0.4 ± 3.6 -1.1 ± 5.1
Distal 1/3 radius aBMD
Low VitD -1.6* ± 2.7 0.10 0.17 -1.3* ± 2.8 0.69 0.67
Moderate VitD -0.5 ± 2.9 -1.6* ± 3.5
Ultradistal radius aBMD
Low VitD -1.3* ± 3.1 0.73 0.53 -1.6* ± 4.2 0.39 0.42
Moderate VitD -1.0 ± 4.2 -0.7 ± 4.7
Vitamin D and bone turnover markers
25-hydroxyvitamin D
Low VitD 45.1* ± 44.1 0.041 28.1* ± 41.9 0.031
Moderate VitD 66.7* ± 78.0 51.2* ± 68.9
Parathyroid hormone
Low VitD -17.7* ± 36.2 0.721 -15.9 ± 71.4 0.568
Moderate VitD -22.5* ± 31.8 -24.2* ± 32.7
P1NP
Low VitD -13.4* ± 38.4 0.527 -8.1 ± 37.3 0.726
Moderate VitD -6.8 ± 35.9 −4.0 ± 41.1
CTX
Low VitD -4.8 ± 51.0 0.315 -9.9 ± 65.3 0.388
Moderate VitD -17.0* ± 37.3 -21.3* ± 42.0

Abbreviations: TBF: total body fat; CTX, C-telopeptide; P1NP, pro-collagen type 1 amino-terminal propeptide

*

p<0.05 for within-group change from baseline